Elanco Animal Health beats Q3 revenue estimates on pet health demand, raises FY outlook
ELAN•Elanco Animal Health reported Q3 revenue of $1.27 billion and adjusted EPS of $0.27, beating consensus estimates of $1.21 billion and $0.20. It raised 2026 revenue guidance to $5.155 billion-$5.18 billion and adjusted EPS guidance to $1.17-$1.20.
1. Q3 results
Q3 revenue rose 11% to $1.27 billion, above the $1.21 billion consensus estimate. Adjusted EPS was $0.27, versus the $0.20 estimate, while net income was $18 million.
2. Raised guidance
Elanco raised its 2026 revenue guidance to $5.155 billion-$5.18 billion from $5.09 billion-$5.14 billion, and its adjusted EPS guidance to $1.17-$1.20 from $1.10-$1.16. The company expects 2027 results to reflect mid-single-digit organic revenue growth and low-double-digit adjusted EPS growth.
3. Growth drivers
The company cited demand for products including Zenrelia and Credelio Quattro, along with 4% price growth, for revenue gains. Adjusted gross margin rose 300 basis points, primarily due to pricing and product mix.
